Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

View Full Paper
Ask AI
Bookmark
Share

Authors

CHChi-Joan HowGHGabriela HobbsKKK. Kan

Discussion

Loading...

Member takes

Overview

Phase I trial evaluates ruxolitinib and ulixertinib, showing potential for complete response in myelofibrosis.

Key Points

  • Combination therapy showed a complete response in myelofibrosis patients previously treated with ruxolitinib.
  • The primary endpoint is complete response defined by IWG-MRT criteria at week 25.
  • Phase I trial used a 3+3 dose escalation design for ulixertinib in myelofibrosis patients receiving ruxolitinib.
  • If successful, this approach may impact treatment strategies for diseases with JAK-STAT signaling.

Cite This Study

How et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df8chttps://doi.org/10.1182/blood-2025-5606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis2025 · 2 citations
  2. 2Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics2025
  3. 3A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia2025 · 2 citations
  4. 4Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study2025 · 6 citations
  5. 5Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025